

PHIGENIX
Exhibit 1032



Making Cancer History™

CURRICULUM VITAE

Michael G. Rosenblum, Ph.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX

Head, Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

OFFICE ADDRESS

M.D. Anderson Cancer Center
1901 East Road
Unit Number: 1950
Houston, TX 77054
Room Number: 3SCR4.3418
Phone: 713-792-3554
Email: mrosenbl@mdanderson.org

EDUCATION

Degree-Granting Education

University of South Carolina, Columbia, SC, BS, 1972, Chemistry

Medical University of South Carolina, Charleston, SC, MS, 1974, Pharmacology

University of Arizona College of Medicine, Tucson, AZ, Ph.D., 1978, Pharmacology

Postgraduate Training

Project Investigator, MD Anderson Cancer Center, Houston, TX, 12/1978–6/1980

Research Associate, MD Anderson Cancer Center, Houston, TX, 6/1980–9/1981

CREDENTIALS

Board Certification

N/A

Licensures

Active

N/A

Inactive

N/A

EXPERIENCE/SERVICE

Academic Appointments

Assistant Professor, Department of Clinical Immunology and Biological Therapy, M.D. Anderson Cancer Center, Houston, TX, 1981–1987

Tenure Awarded 1985

Associate Professor, Department of Bioimmunotherapy, M.D. Anderson Cancer Center, Houston, TX, 1988–1997

Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX, 1997–present

Administrative Appointments/Responsibilities

Head, Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX, 1984–present

Director of Research Development, Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX, 9/2008–2013

Other Appointments/Responsibilities

Associate Pharmacologist, M.D. Anderson Cancer Center, Houston, TX, 1986–1999

Invited Study Section Member (Cancer), Tobacco-Related Disease Research Program (TRDRP), California and Colorado, 5/2000–5/2003

Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 2001–2010

Endowed Positions

N/A

Consultantships

ProNeuron (Formerly Igen, Inc.), Bethesda, Advisory Board Member, 12/1993–1997

Biogen, Inc, Cambridge, Advisory Board Member, 8/1994–1996

Novopharm Biotech, Inc, Winnipeg, Advisory Board Member, 8/1995–2002

Caprion Pharmaceuticals, Montreal, Quebec, Canada, Member, Scientific and Clinical Advisory Board, 2006–2010

Targa Therapeutics, Houston, TX, Founder and Chief Scientific Consultant, 1/2006–12/2010

Thallion Pharmaceuticals, Montreal, Canada, Consultant, CAB, and SAB Member, 1/2010–12/2010

Kyto Pharmaceuticals, Toronto, Canada, Consultant, 1/2010–12/2010

Savoy Pharmaceuticals, Consultant, 1/2011–1/2012

RCT Therapeutics, Inc, 2012–2013

Military or Other Governmental Service

N/A

Institutional Committee Activities

Member, Research Committee, 1983–1989

Member, Investigational Drug Committee, 1983–1992
Member, Biological Response Modifier Committee, Member, 1986–1990
Member, Pharmacy and Therapeutics Committee, 1989–1992
Member, Animal Care and Use Committee, 1990–1993
Member, Education Subcommittee Faculty Achievement Award, 1992
Elected Member, Faculty Senate, 1994–1998
Member, Institutional Biosafety Committee, 1994–1999
Member, Clinical Research Committee, 1995–1999
Elected Member, Immunology Program Steering Committee, 1996–1998
Elected Member, Faculty Senate Executive Committee, 1996–1998
Member, GSBS Admissions Committee for Immunology, 1996–2002
Chair, Faculty Senate Education Committee, 1996–2006
Co-Chair, Institutional Ground Rounds Organization Committee, 1996–present
Member, Research Council, 1997–1998
Member, Faculty Senate/Division of Medicine Liaison Committee, 1997–1998
Member, Promotion and Tenure Task Force, 1997–1999
Co-Chair, CME Steering Committee, 1997–2002
Member, Postdoctoral Program Advisory Committee, 1998–2002
Member, Faculty Senate IS Sub-Committee, 1998
Member, Molecular Targeting Working Group Focusing on Aerodigestive Cancers, 2000–2001
Member, Clinical & Translational Research Center (CTRC) Review Committee, 2001–2002
Member, Oversight Committee of the Cancer Therapeutics Discovery Program, 2001–2003
Member, Radioactive Drug Research Committee, 2001–2004
Member, Education Council, 2001–2007
Member, Institutional Cancer Therapeutics Development Program, 2002–present
Member, MDACC “Technology Champions” Group, 2002–2012
Elected Representative, Faculty Senate - Experimental Therapeutics Department, 2003–2011
Elected Member, Faculty Senate Executive Committee, 2005–2011
Member, MDACC Conflict of Interest Committee, 2005-present
Vice-Chair, MDACC Conflict of Interest Committee, 2007–2009
Chair, MDACC Conflict of Interest Committee, 2009-2011
Past Chair, MDACC Conflict of Interest Committee, 2011-present
Member, MDACC Technology Review Committee, 2010–2013
Chair, Faculty Senate Faculty Achievement Awards Committee, 2011-2014
Member, Executive Committee of the Science Faculty, 2007–2012
Member, Experimental Therapeutics Management Team, 2008–2013

Member, ET Seminar Series Committee, 2008-present
 Chair, New Perspectives in Targeted Biomolecules Seminar Series(ET) 2009-2012
 Chair, MDACC Blue Ribbon Panel on Conflict of Interest Policy Review, 2011-2012
 Chair, MDACC Blue Ribbon Panel on IACUC Policies/Enforcement, 2013
 Member, MDACC Bridge Funding Committee, 2011-present
 Member, Executive Research Compliance Committee, 2011-present
 MDACC Senior Officer for Research Integrity, 9/2013-present

HONORS AND AWARDS

N/A

RESEARCH

Grants and Contracts

Funded

Co-Principal Investigator, 0.12 months, Development of Therapeutic Agents Targeting the FN14 Receptor for TWEAK, R01 NS55126, NIH/NCI, 12/1/2009–11/30/2012, NCE, \$83,116 (\$41,558/year)

Principal Investigator, 2.88 months, Monoclonal Antibody Delivery Systems, Clayton Foundation for Research, 12/1987–Present \$500,000 (\$500,000/year)

Principal Investigator, 1.2 months, Application of Photochemical Internalization to optimize delivery of VEGF121-rGel to the vasculature of invasive solid tumors, UT MDACC Sister Institution Network Fund, 9/1/2012–8/31/2014, \$100,000 (\$50,000/year)

Co-Investigator, 0.48 months, GrB-TWEAK: A Potential Novel Biologic for NSCLC Therapy, DOD Lung Cancer Idea Award, 10/1/2014–9/30/2015, \$33,869/year

Pending

Co-Investigator, 0.48 months, Development of Fn-14 Targeted, GrB-Based Agents for NSCLC Therapy, NIH/NCI, PI - Winkles, 7/1/2014–6/30/2015 (\$30,794/year)

Other

N/A

Completed

Co-Investigator, Correlated clinical-laboratory Phase I trials, UO1 CA62461-06, NIH/NCI, 2/1/1998–1/31/2003, \$1,671,168 (\$334,234/year)

Co-Investigator, Bioimmunotherapy training grant, 1P32CA72321-1A1, American Institute for Cancer Research (AICR), 9/30/1998–7/31/2002, \$961,655 (\$192,331/year)

Principal Investigator, Molecular engineering to retarget human cytokines, DAMD17-99-1-9259-2 BC980048, Department of Defense (DOD), 7/1/1999–6/30/2002, \$263,461 (\$65,865/year)

Co-Investigator, New agents for Taxol-resistant ovarian carcinoma, OC990052, DOD Ovarian Cancer Research Program, 10/20/1999–10/19/2002, \$450,016 (\$11,252/year)

Principal Investigator, Evaluation of novel agents which targets neovasculature of bladder tumors, N/A, Developmental Research Award Bladder Cancer SPORE Grant, 12/1/2001–11/30/2002, \$40,000 (\$40,000/year)

Principal Investigator, 1.2 months, Protein fermentation and manufacturing, Clayton Foundation for Research, 9/1/2003–12/31/2012, \$115,000 (\$115,000/year)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.